Understanding how Factor XII affects complications in sickle cell disease
Official title: Role of Factor XII in Thrombo-Inflammatory Complications of Sickle Cell Disease
Funded at Univ of North Carolina Chapel Hill · NIH-10859580 · Data updated 2026-11-12
This study is looking at how a protein called Factor XII affects sickle cell disease and its complications, like blood clots and painful crises, to see if a special treatment can help reduce these issues for people living with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | July 15, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $724,727 |
| NIH project number | 1R01HL173322-01 |
| Project ID | NIH-10859580 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with sickle cell disease who experience recurrent vaso-occlusive crises or venous thrombosis.
✕Less likely to help
Patients without a diagnosis of sickle cell disease or those who do not experience thrombo-inflammatory complications may not benefit from this research.
What this research studies
This research investigates the role of Factor XII in sickle cell disease (SCD) and how it contributes to complications such as venous thrombosis and vaso-occlusive crises. The study aims to characterize the functions of Factor XII and its impact on neutrophil activation and adhesion, which are critical in the disease's progression. By exploring the effects of an anti-FXII antibody that blocks its functions, the research seeks to identify potential new therapies that could reduce complications associated with SCD.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the painful complications and organ damage associated with sickle cell disease.
How similar studies have gone: Previous studies have shown promising results in targeting Factor XII for therapeutic purposes, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Pawlinski, Rafal L — Univ of North Carolina Chapel Hill
- Study coordinator: Pawlinski, Rafal L
Related research
Other NIH-funded projects on the same topics.
-
Digital twins of the spleen to help design better therapies for sickle cell disease
A computer-driven replica of the spleen is being developed to speed up creating safer and more effective treatments for people with sickle cell disease.
-
Accelerating hydroxyurea use for sickle cell disease in Nigeria
A pragmatic study in Nigeria aims to help doctors use hydroxyurea more consistently for people with sickle cell disease.
-
Immune and nerve signals behind acupuncture relief for sickle cell pain
This NIH grant explores how acupuncture helps reduce pain and opioid use for people with sickle cell disease.
-
Mindfulness-based Support for Pain and Sleep in Young People with Sickle Cell Disease
A digital mindfulness program is being tailored for adolescents and young adults with sickle cell disease to help with pain and sleep and is being tested for practicality and early effectiveness.
-
How diet affects white blood cells and sickle cell disease
A study looks at how nutrition, from early life to adulthood, influences sickle cell disease by examining neutrophils and disease severity in people with SCD and in a mouse model.
-
Nutrition-based plan to ease pain in sickle cell disease
A nutrition-based approach is being tested to reduce pain for people living with sickle cell disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.